One-Year Anniversary of Pandemic Is Remembered Through Giving Back and Humanitarian Efforts From It Works!

Mark Pentecost, It Works! CEO and entrepreneur, advocates for philanthropy now more than ever as communities look to…

Chubb Introduces New and Modernized Package Product for Commercial Clients

Chubb has introduced a new insurance product, Benchmarq Package, for the lower middle market segment, setting…

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA

Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical…

HEALTHdrum’s Digital Health Platform Challenges Sick Healthcare System

HEALTHdrum.com LLC, a Boca Raton healthcare technology company, announced today the launch of their cost-transparent healthcare marketplace platform…

amg International GmbH, a Q3 Medical Devices Ltd Company,

 amg International GmbH (“amg” or the “Company”), a wholly owned subsidiary of Dublin, Ireland based Q3 Medical Devices…

Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory…

Tivity Health to Participate in Upcoming Investor Conferences

Tivity Health, Inc. (NASDAQ: TVTY) today announced that it will participate in the following virtual investor conferences:…

Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

 Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central…

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies…

Novartis to unveil new data at ASCO and EHA from its robust portfolio

Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and…